These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 17038832)

  • 21. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.
    Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
    Tang RS; Spaete RR; Thompson MW; MacPhail M; Guzzetta JM; Ryan PC; Reisinger K; Chandler P; Hilty M; Walker RE; Gomez MM; Losonsky GA
    Vaccine; 2008 Nov; 26(50):6373-82. PubMed ID: 18822334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Live-attenuated Vaccines Prevent Respiratory Syncytial Virus-associated Illness in Young Children.
    Karron RA; Atwell JE; McFarland EJ; Cunningham CK; Muresan P; Perlowski C; Libous J; Spector SA; Yogev R; Aziz M; Woods S; Wanionek K; Collins PL; Buchholz UJ
    Am J Respir Crit Care Med; 2021 Mar; 203(5):594-603. PubMed ID: 32871092
    [No Abstract]   [Full Text] [Related]  

  • 24. PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease.
    Wang EE; Law BJ; Robinson JL; Dobson S; al Jumaah S; Stephens D; Boucher FD; McDonald J; Mitchell I; MacDonald NE
    Pediatrics; 1997 Mar; 99(3):E9. PubMed ID: 9099774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention.
    Stewart DL; Romero JR; Buysman EK; Fernandes AW; Mahadevia PJ
    Curr Med Res Opin; 2009 Nov; 25(11):2795-804. PubMed ID: 19788406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of maternal RSV vaccine to protect infants in Gavi-supported countries: Estimates from two models.
    Baral R; Li X; Willem L; Antillon M; Vilajeliu A; Jit M; Beutels P; Pecenka C
    Vaccine; 2020 Jul; 38(33):5139-5147. PubMed ID: 32586761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimates of the national burden of respiratory syncytial virus in Kenyan children aged under 5 years, 2010-2018.
    Nyawanda BO; Murunga N; Otieno NA; Bigogo G; Nyiro JU; Vodicka E; Bulterys M; Nokes DJ; Munywoki PK; Emukule GO
    BMC Med; 2023 Mar; 21(1):122. PubMed ID: 37004034
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RSV associated hospitalizations in children in Karachi, Pakistan: Implications for vaccine prevention strategies.
    Ali A; Yousafzai MT; Waris R; Jafri F; Aziz F; Abbasi IN; Zaidi A
    J Med Virol; 2017 Jul; 89(7):1151-1157. PubMed ID: 28092107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007-2012.
    Reeves RM; Hardelid P; Gilbert R; Warburton F; Ellis J; Pebody RG
    Influenza Other Respir Viruses; 2017 Mar; 11(2):122-129. PubMed ID: 28058797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shift in Clinical Epidemiology of Human Parainfluenza Virus Type 3 and Respiratory Syncytial Virus B Infections in Korean Children Before and During the COVID-19 Pandemic: A Multicenter Retrospective Study.
    Kim YK; Song SH; Ahn B; Lee JK; Choi JH; Choi SH; Yun KW; Choi EH
    J Korean Med Sci; 2022 Jul; 37(28):e215. PubMed ID: 35851860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare costs within a year of respiratory syncytial virus among Medicaid infants.
    Palmer L; Hall CB; Katkin JP; Shi N; Masaquel AS; McLaurin KK; Mahadevia PJ
    Pediatr Pulmonol; 2010 Aug; 45(8):772-81. PubMed ID: 20632403
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and epidemiological characteristics of acute respiratory virus infections in Vietnamese children.
    Tran DN; Trinh QD; Pham NT; Vu MP; Ha MT; Nguyen TQ; Okitsu S; Hayakawa S; Mizuguchi M; Ushijima H
    Epidemiol Infect; 2016 Feb; 144(3):527-36. PubMed ID: 26145204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Costs of hospitalization with respiratory syncytial virus illness among children aged <5 years and the financial impact on households in Bangladesh, 2010.
    Bhuiyan MU; Luby SP; Alamgir NI; Homaira N; Sturm-Ramirez K; Gurley ES; Abedin J; Zaman RU; Alamgir A; Rahman M; Ortega-Sanchez IR; Azziz-Baumgartner E
    J Glob Health; 2017 Jun; 7(1):010412. PubMed ID: 28702175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries.
    Li X; Willem L; Antillon M; Bilcke J; Jit M; Beutels P
    BMC Med; 2020 Apr; 18(1):82. PubMed ID: 32248817
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials.
    Fisher RG; Gruber WC; Edwards KM; Reed GW; Tollefson SJ; Thompson JM; Wright PF
    Pediatrics; 1997 Feb; 99(2):E7. PubMed ID: 9099764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling the household-level impact of a maternal respiratory syncytial virus (RSV) vaccine in a high-income setting.
    Campbell PT; Geard N; Hogan AB
    BMC Med; 2020 Nov; 18(1):319. PubMed ID: 33176774
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
    Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
    J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.